遠大醫藥(00512.HK)簽訂兩份股份購買協議並獲Telix藥品大中華獨家授權
遠大醫藥(00512.HK)公布,與Telix集團達成合作,雙方簽訂股份認購協議,公司將以2,500萬美元認購Telix約7.6%股本權益,並與Telix簽訂獨家授權、合作開發及商業化協議,累計將支付預付款及里程碑款項最多2.25億美元,以獲得Telix開發之已完成II期臨床試驗的前列腺癌藥物「TLX591」、即將開展兩個聯用免疫藥物的II期臨床試驗的用於治療透明細胞腎細胞癌藥物「TLX250」,及已獲得FDA孤兒藥認定及處於I/II期臨床階段的用於治療膠質母細胞瘤藥物「TLX101」等多款放射性核素偶聯藥物於大中華地區之獨家開發、生產及商業化權益。
另外公司並與Telix簽訂獨家商業合作協議,將獲得Telix開發之已向FDA提交新藥申請的用於前列腺癌影像診斷之「TLX591-CDx」、已獲得FDA突破性療法認定並處於III期臨床階段的用於透明細胞腎細胞癌的影像診斷「TLX250-CDx」,及用於前列腺癌影像診斷的「TLX599-CDx」在內的多款放射性核素偶聯藥物在大中華地區的生產及商業化權益。
另外公司與江蘇省原子醫學研究所簽訂戰略合作備忘錄,就放射性核素偶藥物領域的藥物研發、生產、檢測及標準制定、臨床前研究以及知識產權等領域合作內容達成一致意向,建立良好的合作機制並開展長期合作,逐步提高公司放射性核素偶聯藥物的開發、臨床前研究及產品轉化等能力。
公司亦與普爾偉業簽署股份購買協議,將以最多1,000萬元人民幣代價收購普爾偉業全數股權。完成收購後,普爾偉業將成公司附屬,公司亦將獲得《放射性藥品生產許可證》及《放射性藥品經營許可證》,並獲得在中國開展68Ga、177Lu、89Zr、90Y等多種放射性核素偶聯藥物的開發、生產及經營的相關資質。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.